Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).
Georgios TsakonasLena SpechtClaus Andrup KristensenMaria Herlestam Calero MorenoHedda Haugen CangeKarin SöderkvistSigne FrieslandPublished in: Cancers (2020)
Cetuximab and paclitaxel/carboplatin was found to have similar efficacy and less toxicity compared to cetuximab and 5-FU/cisplatin or carboplatin. The experimental arm is easier to administer rendering it a favorable alternative to standard therapy.
Keyphrases
- phase ii study
- locally advanced
- squamous cell carcinoma
- rectal cancer
- open label
- phase iii
- radiation therapy
- metastatic colorectal cancer
- phase ii
- placebo controlled
- acute lymphoblastic leukemia
- double blind
- clinical trial
- acute myeloid leukemia
- study protocol
- lymph node metastasis
- small cell lung cancer
- wild type
- diffuse large b cell lymphoma
- multiple myeloma
- stem cells
- randomized controlled trial
- hodgkin lymphoma
- chemotherapy induced
- smoking cessation